pharmaphorum

MAY 27, 2022

Once stakeholders are confident that technologies are adequately validated, selection based on scientific and ethical considerations can be presented to regulators in accordance with applicable legal and regulatory frameworks. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials.

Clinical Trials 80

Clinical Trials Clinical Trials Trials Packaging 80

Drug Discovery World

AUGUST 10, 2023

Thinking about the key potential consumers of data will help build its value beyond the regulatory compliance use case, and shift regulatory’s role within the enterprise as a data producer. What frustrates you in terms of what companies still haven’t realised, or aren’t doing – and what should they do differently in 2023?

Production 98

Production Life Science Development Manufacturing 98

Pharmaceutical Technology

MARCH 29, 2023

While regulations will be a key influence behind the types of CCIT methods that pharma companies deploy, manufacturers must also weigh up their own requirements for efficiency and quality when choosing a system. blue dye ingress, microbial ingress) towards deterministic ones.

Containment 130

Containment Production Packaging Packaging 130

Pharmaceutical Technology

NOVEMBER 30, 2022

A vitally important assay used across various stages of drug development and manufacturing, container closure integrity testing (CCIT) involves evaluating packaging systems to determine their ability to protect the stability and sterility of pharmaceutical products. Encouraged by the regulations, the industry is now mid-transition.

Containment 130

Containment Manufacturing Production Regulation 130